Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – WHOLLY-OWNED SUBSIDIARY PASSING FDA ON-SITE INSPECTION

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 22 October 2025.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, Suzhou Union Biopharm Co., Ltd.* (蘇州眾合生物醫藥科技有限公司) ("**Suzhou Union**"), a wholly-owned subsidiary of the Company, underwent an unannounced inspection (i.e., an inspection conducted without prior notification during routine operations) in respect of Current Good Manufacturing Practice ("**CGMP**") by the U.S. Food and Drug Administration (the "**FDA**") from 16 June 2025 to 24 June 2025. Suzhou Union has recently received the Establishment Inspection Report (EIR) issued by the FDA, which confirms that Suzhou Union has passed the CGMP on-site inspection. The relevant particulars are hereby announced as follows:

INFORMATION ABOUT THE FDA ON-SITE INSPECTION

Company name: Suzhou Union Biopharm Co., Ltd.*
Inspection location: 999 Longqiao Road, Wujiang Economic and Industrial Development Zone, Suzhou (Suzhou Wujiang Production Base)
Underlying product: Toripalimab injection
FDA FEI: 3014164694

IMPLICATIONS ON THE COMPANY

This marks Suzhou Union's second successful pass of FDA on-site inspection since its initial success in 2023, demonstrating that the Company's high-quality production and manufacturing system continues to gain international recognition. As of the date of this announcement, with a fermentation capacity of 4,500L (9*500L), Suzhou Wujiang Production Base has obtained GMP certifications and approvals from various countries and regions, including Chinese mainland, Hong Kong SAR, China, the United States, the European Union, the United Kingdom, Australia, Singapore, India, Jordan, the United Arab Emirates, Kuwait and Pakistan, etc., and is responsible for the commercial supply of toripalimab for overseas markets.

The U.S. market is an important component of the overseas commercialization strategy of the Company. The successful pass of FDA on-site inspection provides a solid foundation for the Company's continued expansion in the U.S. market, which will have a positive impact on the production and operations of the Company.

RISK WARNING

The Company expects that the inspection will not have a significant impact on the results of the Company in the short term. As the production and sale of drugs is susceptible to various factors, including change in market environment, thus leading to uncertainty, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above project and fulfill its information disclosure obligations in a timely manner in respect of the subsequent progress of the project in strict compliance with relevant regulations.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 22 October 2025

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purpose only*